To access this element change to forms mode OFF
Grant Award View - GA314734
REZOLV3R: Randomised trial of palliative intraperitoneal bevacizumab...
GA ID:
GA314734
Agency:
Cancer Australia
Approval Date:
19-Jun-2023
Publish Date:
23-Jun-2023
Category:
Cancer
Grant Term:
30-Jun-2023 to 29-Jun-2026
Value (AUD):
$600,000.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 22/23 Improved cancer control
Grant Program:
2022 Priority-driven Collaborative Cancer Research Scheme (PdCCRS)
Grant Activity:
REZOLV3R: Randomised trial of palliative intraperitoneal bevacizumab following therapeutic drainage of recurrent malignant ascites in patients with chemotherapy resistant solid tumours
Purpose:
Malignant ascites (fluid in the abdomen) is troublesome in advanced cancers and no treatments are approved in Australia. Usual treatment is repeated drainage of fluid from the abdomen (paracentesis). A phase 2 trial showed that bevacizumab given into the abdomen after paracentesis safely increased the time until ascites recurred, delaying or avoiding hospital visits and reducing symptom burden; in this trial the investigators aim to gather stronger evidence and improve comfort and quality of life for people with malignant ascites.
GO ID:
GO Title:
2022 Priority-driven Collaborative Cancer Research Scheme for funding commencing 2023
Internal Reference ID:
2023805_Sjoquist
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Sydney
Postcode:
2006
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA